Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Cash & Equivalents (2016 - 2025)

CV Sciences' Cash & Equivalents history spans 14 years, with the latest figure at $381000.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 61.08% year-over-year to $381000.0; the TTM value through Sep 2025 reached $381000.0, down 61.08%, while the annual FY2024 figure was $454000.0, 65.53% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $381000.0 at CV Sciences, down from $886000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $5.2 million in Q1 2021 and bottomed at $381000.0 in Q3 2025.
  • The 5-year median for Cash & Equivalents is $1.0 million (2022), against an average of $1.4 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 115.55% in 2023 before it plummeted 71.78% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $1.4 million in 2021, then crashed by 55.56% to $611000.0 in 2022, then surged by 115.55% to $1.3 million in 2023, then crashed by 65.53% to $454000.0 in 2024, then dropped by 16.08% to $381000.0 in 2025.
  • Per Business Quant, the three most recent readings for CVSI's Cash & Equivalents are $381000.0 (Q3 2025), $886000.0 (Q2 2025), and $812000.0 (Q1 2025).